Orion
73.65 EUR
+0.82 %
14,366 following
ORNBV
NASDAQ Helsinki
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Dividend
Investor consensus
+0.82 %
+6.05 %
+5.59 %
+15.71 %
+8.79 %
+47.54 %
+66.82 %
+109.77 %
+555.83 %
Orion operates in the pharmaceutical industry. The company conducts research and development of human and veterinary drugs, where the main focus is on diseases that affect the nervous system, as well as oncology and respiratory diseases. Today, the company's products are found on a global level, with the largest presence in the Nordic region and the rest of Europe. The company's head office is located in Espoo, Finland.
Read moreMarket cap
10.39B EUR
Turnover
8.18M EUR
P/E (adj.) (26e)
18.94
EV/EBIT (adj.) (26e)
14.75
P/B (26e)
6.54
EV/S (26e)
5.01
Dividend yield-% (26e)
2.42 %
Latest research
Latest analysis report
Released: 01.04.2026
Revenue and EBIT-%
Revenue B
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
23.4
2026
Interim report Q1'26
17.7
2026
Interim report Q2'26
19.10
2026
Half year dividend
Risk
Business risk
Valuation risk
Low
High
All
Research
Webcasts
Press releases
ShowingAll content types
Orion, Webcast, Q1'26
Change in Orion Group Executive Team as of 8 April 2026 – Berkeley Vincent appointed Executive Vice President, Innovative Medicines
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
